Tzipori S, Rand W, Griffiths J, Widmer G, Crabb J
Department of Comparative Medicine, Tufts University School of Veterinary Medicine, Grafton, Massachusetts 01536, USA.
Clin Diagn Lab Immunol. 1994 Jul;1(4):450-63. doi: 10.1128/cdli.1.4.450-463.1994.
Several immunodeficient rodent models currently exist in which persistent, largely asymptomatic, Cryptosporidium parvum infections can be established. Piglets, in contrast, develop a self-limiting diarrheal illness. We have consequently developed an animal model system in which scid mice were used to screen drugs for inhibitory activity against C. parvum, after which the drugs' therapeutic potential was evaluated with piglets. Paromomycin and hyperimmune bovine colostrum-immunoglobulin were selected to evaluate this system. C. paravum infections in suckling scid mice tended to be associated with villus surfaces, while in weaned and in older scid mice infections were more commonly localized in abscessed crypts. Rates of oocyst shedding in suckling scid mice were 50 to 200 times higher than in weaned mice and therefore made suckling mice a considerably more sensitive model for drug testing. Paromomycin given in high doses over 9 to 10 days was not toxic to either scid mice (3,000 mg/kg of body weight per day) or piglets (500 mg/kg/day). Paromomycin treatment was very effective against villus surface infections in suckling mice and considerably less effective against infections in inaccessible sites such as abscessed crypts and stomach pits seen in weaned and adult scid mice. The therapeutic efficacy of paromomycin in piglets depended on the severity of the diarrheal illness. Mild to moderate diarrhea and infection were cleared after paromomycin treatment of piglets infected with one C. parvum isolate. However, paromomycin had no impact on severely affected piglets infected with a second isolate, presumably because of a rapid transit time through the gut. In contrast to paromomycin hyperimmune bovine colostrum-immunoglobulin treatment reduced the rate of C. parvum infection moderately in scid mice and only slightly in piglets, again probably because of a rapid transit time through the gut and inactivation in the stomach. It was also clear that the impact of effective drugs against C. parvum can be detected within 5 days after the onset of treatment in either model.
目前存在几种免疫缺陷啮齿动物模型,在这些模型中可以建立持续的、基本无症状的微小隐孢子虫感染。相比之下,仔猪会患上一种自限性腹泻疾病。因此,我们开发了一种动物模型系统,其中使用重度联合免疫缺陷(scid)小鼠筛选对微小隐孢子虫具有抑制活性的药物,之后用仔猪评估这些药物的治疗潜力。选择巴龙霉素和超免疫牛初乳免疫球蛋白来评估该系统。哺乳的scid小鼠中的微小隐孢子虫感染往往与绒毛表面有关,而在断奶和年龄较大的scid小鼠中,感染更常见于脓肿隐窝。哺乳scid小鼠的卵囊排出率比断奶小鼠高50至200倍,因此使哺乳小鼠成为药物测试的一个更为敏感的模型。在9至10天内给予高剂量的巴龙霉素对scid小鼠(每天3000毫克/千克体重)或仔猪(500毫克/千克/天)均无毒。巴龙霉素治疗对哺乳小鼠的绒毛表面感染非常有效,而对断奶和成年scid小鼠中难以触及部位(如脓肿隐窝和胃小凹)的感染效果则要差得多。巴龙霉素对仔猪的治疗效果取决于腹泻疾病的严重程度。用一种微小隐孢子虫分离株感染的仔猪经巴龙霉素治疗后,轻度至中度腹泻和感染得以清除。然而,巴龙霉素对感染第二种分离株的严重受影响仔猪没有作用,可能是因为其在肠道内的通过时间很快。与巴龙霉素不同,超免疫牛初乳免疫球蛋白治疗在scid小鼠中适度降低了微小隐孢子虫感染率,在仔猪中仅略有降低,同样可能是因为其在肠道内的通过时间很快且在胃中失活。同样明显的是,在任一模型中,治疗开始后5天内即可检测到有效药物对微小隐孢子虫的影响。